Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UBX
Previous Symbol
CUSIPN/A
WebN/A
PhoneN/A
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares42,320,000
Market Cap$531.15 million
OptionableNot Optionable
Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions
What is Unity Biotechnology's stock symbol?
Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."
When is Unity Biotechnology's next earnings date?
What price target have analysts set for UBX?
4 brokerages have issued 12 month target prices for Unity Biotechnology's stock. Their predictions range from $17.00 to $33.00. On average, they expect Unity Biotechnology's stock price to reach $26.75 in the next twelve months. This suggests a possible upside of 122.9% from the stock's current price. View Analyst Price Targets for Unity Biotechnology.
What is the consensus analysts' recommendation for Unity Biotechnology?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unity Biotechnology.
Has Unity Biotechnology been receiving favorable news coverage?
Press coverage about UBX stock has trended somewhat negative on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Unity Biotechnology earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of Unity Biotechnology's key competitors?
Some companies that are related to Unity Biotechnology include Heron Therapeutics (HRTX), Udg Healthcare (UDHCF), INDIVIOR PLC/S (INVVY), Medpace (MEDP), Amicus Therapeutics (FOLD), BioTelemetry (BEAT), Glaukos (GKOS), Global Blood Therapeutics (GBT), Aerie Pharmaceuticals (AERI), Pacira Pharmaceuticals (PCRX), Opko Health (OPK), Endocyte (ECYT), NxStage Medical (NXTM), CONMED (CNMD) and Crispr Therapeutics (CRSP).
Who are Unity Biotechnology's key executives?
Unity Biotechnology's management team includes the folowing people:
- Mr. Keith R. Leonard Jr., Exec. Chairman & CEO (Age 56)
- Dr. Nathaniel E. David, Co-Founder, Pres & Director (Age 50)
- Dr. Jan M. van Deursen, Founder
- Dr. Judith Campisi Ph.D., Founder
- Mr. Daohong Zhou M.D., Founder
When did Unity Biotechnology IPO?
(UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.
When did the company's lock-up period expire?
Unity Biotechnology's lock-up period expired on Tuesday, October 30th. Unity Biotechnology had issued 5,000,000 shares in its initial public offering on May 3rd. The total size of the offering was $85,000,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.
Who are Unity Biotechnology's major shareholders?
Unity Biotechnology's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (8.42%), Capital World Investors (2.45%), EcoR1 Capital LLC (2.29%), BlackRock Inc. (0.81%), Artal Group S.A. (0.12%) and Bank of New York Mellon Corp (0.04%).
Which major investors are selling Unity Biotechnology stock?
UBX stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC and Artal Group S.A..
Which major investors are buying Unity Biotechnology stock?
UBX stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, BlackRock Inc., FMR LLC and Bank of New York Mellon Corp.
How do I buy shares of Unity Biotechnology?
Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Unity Biotechnology's stock price today?
One share of UBX stock can currently be purchased for approximately $12.00.
How big of a company is Unity Biotechnology?
Unity Biotechnology has a market capitalization of $531.15 million.
MarketBeat Community Rating for Unity Biotechnology (NASDAQ UBX)
MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote "Outperform" if you believe UBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
